Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SUV39H2 | Q9H5I1 | 15/20 | 0.52 |
| ▸ | CKS1B | P61024 | 1/20 | 0.52 |
| ▸ | SKP1 | P63208 | 1/20 | 0.52 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.52 |
| ▸ | JAK3 | P52333 | 1/20 | 0.43 |
| ▸ | BTK | Q06187 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24851466 | 0.88 | CKS1B (0.54) | SUV39H2CKS1BSKP1SKP2JAK3 | |
| SCHEMBL5222133 | 0.86 | CKS1B (0.51) | SUV39H2CKS1BSKP1SKP2JAK3 | |
| SCHEMBL9900445 | 0.85 | HPGD (0.46) | CKS1BSKP1SKP2 | |
| SCHEMBL9942511 | 0.84 | ALDH1A1 (0.51) | SUV39H2CKS1BSKP1SKP2JAK3 | |
| SCHEMBL27449378 | 0.83 | SUV39H2 (0.53) | SUV39H2CKS1BSKP1SKP2JAK3 | |
| SCHEMBL24851725 | 0.83 | BTK (0.57) | SUV39H2CKS1BSKP1SKP2JAK3 | |
| SCHEMBL17085624 | 0.82 | CKS1B (0.53) | SUV39H2CKS1BSKP1SKP2BTK | |
| SCHEMBL15446618 | 0.81 | CKS1B (0.54) | SUV39H2CKS1BSKP1SKP2JAK3 | |
| SCHEMBL3281615 | 0.80 | CKS1B (0.52) | SUV39H2CKS1BSKP1SKP2JAK3 | |
| SCHEMBL31539345 | 0.80 | BTK (0.55) | SUV39H2CKS1BSKP1SKP2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9090593-B2 | Bicyclic compounds as Pim inhibitors | AMGEN INC. (US) | 2015-07-28 | — | — | US | disclosed |
| US-9090593-B2 | Bicyclic compounds as Pim inhibitors | AMGEN INC. (US) | 2015-07-28 | — | — | US | disclosed |
| EP-2796456-A1 | Bicyclic compounds as Pim inhibitors | Amgen Inc. (US) | 2014-10-29 | — | — | EP | disclosed |
| US-20140031360-A1 | BICYCLIC COMPOUNDS AS PIM INHIBITORS | AMGEN INC. (US) | 2014-01-30 | — | — | US | disclosed |
| US-20140031360-A1 | BICYCLIC COMPOUNDS AS PIM INHIBITORS | AMGEN INC. (US) | 2014-01-30 | — | — | US | disclosed |
| WO-2012078777-A1 | BICYCLIC COMPOUNDS AS PIM INHIBITORS | AMGEN INC. (US) | 2012-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140031360-A1 | BICYCLIC COMPOUNDS AS PIM INHIBITORS | PIM1, PIM2, PIM3 | SUV39H2 1715/4885CKS1B 342/4885SKP1 176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.